Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck Tumors.

IF 1.8 Q3 ONCOLOGY

Journal of Cancer Epidemiology Pub Date : 2020-11-12 eCollection Date: 2020-01-01 DOI:10.1155/2020/5615303

Precious Barnes, F A Yeboah, Jinling Zhu, Roland Osei Saahene, Christian Obirikorang, Michael Buenor Adinortey, Benjamin Amoani, Foster Kyei, Patrick Akakpo, Yaw Asante Awuku

{"title":"Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck Tumors.","authors":"Precious Barnes, F A Yeboah, Jinling Zhu, Roland Osei Saahene, Christian Obirikorang, Michael Buenor Adinortey, Benjamin Amoani, Foster Kyei, Patrick Akakpo, Yaw Asante Awuku","doi":"10.1155/2020/5615303","DOIUrl":null,"url":null,"abstract":"Introduction: Head and neck tumors (HNT) are tumors that normally occur at the head and neck region of the body. Epidermal growth factor receptor (EGFR) has been found to be highly expressed in breast and other tumors; therefore, there is the need to investigate the level of EGFR expression among patients with head and neck tumors in Ghana.Method: The level of EGFR expression was determined in head and neck tumor and control head and neck tissues with quantitative real-time PCR and immunohistochemistry analysis.Results: The level of EGFR expressions was high in tumor tissues than in the control tissues. There was a significant difference of p value 0.025 among the ages >40 and ≤ 40 when the high and low level of EGFR was compared in the head and neck malignant tumor. The area under the curve for the high expression of EGFR among the malignant head and neck tumors was 0.901 with a specificity of 86.4%.Conclusion: EGFR can serve as a prognostic marker in monitoring patients with HNT as well as a molecular therapeutic target.","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":"2020 ","pages":"5615303"},"PeriodicalIF":1.8000,"publicationDate":"2020-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2020/5615303","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Epidemiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2020/5615303","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Introduction: Head and neck tumors (HNT) are tumors that normally occur at the head and neck region of the body. Epidermal growth factor receptor (EGFR) has been found to be highly expressed in breast and other tumors; therefore, there is the need to investigate the level of EGFR expression among patients with head and neck tumors in Ghana.

Method: The level of EGFR expression was determined in head and neck tumor and control head and neck tissues with quantitative real-time PCR and immunohistochemistry analysis.

Results: The level of EGFR expressions was high in tumor tissues than in the control tissues. There was a significant difference of p value 0.025 among the ages >40 and ≤ 40 when the high and low level of EGFR was compared in the head and neck malignant tumor. The area under the curve for the high expression of EGFR among the malignant head and neck tumors was 0.901 with a specificity of 86.4%.

Conclusion: EGFR can serve as a prognostic marker in monitoring patients with HNT as well as a molecular therapeutic target.

Abstract Image

查看原文本刊更多论文

头颈部肿瘤患者表皮生长因子受体(EGFR)的预后价值。

头颈部肿瘤(HNT)是通常发生在身体头颈部的肿瘤。表皮生长因子受体(EGFR)已被发现在乳腺和其他肿瘤中高表达;因此，有必要研究加纳头颈部肿瘤患者中EGFR的表达水平。方法:采用实时荧光定量PCR和免疫组织化学方法检测头颈部肿瘤组织和对照头颈部组织中EGFR的表达水平。结果:肿瘤组织中EGFR表达水平明显高于对照组织。头颈部恶性肿瘤中EGFR高、低水平比较，年龄>40岁与≤40岁之间差异有统计学意义，p值为0.025。EGFR在头颈部恶性肿瘤高表达的曲线下面积为0.901，特异性为86.4%。结论:EGFR可作为监测HNT患者的预后指标和分子治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cancer Epidemiology ONCOLOGY-

CiteScore

4.00

自引率

0.00%

发文量

审稿时长

20 weeks

期刊介绍： Journal of Cancer Epidemiology is a peer-reviewed, open access journal that publishes original research articles, review articles, case reports, and clinical studies in all areas of cancer epidemiology.